Essential tremor is characterized by involuntary trembling of the arms and hands, and in many cases of the head and voice as well. It is frequently mild enough that many patients do not seek any medical attention, though in severe cases it can impair eating, drinking, writing and other daily activities, and some patients with the most debilitating symptoms will seek surgery to control it. It appears in some individuals when they are in their twenties and thirties, but becomes more common in later life and is believed to affect as many as 1 in 7 people over the age of 65. Approximately 20% of the general population carry one copy of the at-risk version of the SNP and 5% carry two copies, corresponding to a roughly 55% and 140% higher likelihood of developing the condition than individuals who carry no copies of the risk variant.
deCODE and its collaborators at Vienna, Tubingen and Emory universities would like to thank the individuals who took part in this study.
deCODE is a bio-pharmaceutical company developing drugs and DNA-based
tests to improve the treatment, diagnosis and prevention of common diseases.
Its lead therapeutic programs, which leverage the company's expertise in
chemistry and structural biology, include DG041, an antiplatelet compound
being developed for the prevention of arterial thrombosis; DG051 and DG031,
compounds targeting the leukotriene pathway for the prevention of heart
attack; and DG071 and a platform for other PDE4 modulators with therapeutic
applications in Alzheimer's disease and other conditions. deCODE is a global
leader in human genetics, and has identified key variations in the genome
(SNPs) conferring increased risk of major public health challenges from
cardiovascular disease to cancer. Based upon these discoveries
|SOURCE DeCODE Genetics Inc|
Copyright©2009 PR Newswire.
All rights reserved